loading
Aileron Therapeutics Inc stock is traded at $0.00, with a volume of 0. It is down -100.00% in the last 24 hours and down -100.00% over the past month. Aileron Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects. The company currently has two product candidates in clinical development, LTI-03 and LTI-01, and multiple candidates in preclinical development focused on fibrosis indications.
See More
Previous Close:
$2.11
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$45.72M
Revenue:
-
Net Income/Loss:
$-12.94M
P/E Ratio:
0.00
EPS:
-2.84
Net Cash Flow:
$-13.83M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
Value
$0.00
$0.00
1-Week Range:
Value
$0.00
$0.00
52-Week Range:
Value
$0.00
$4.40

Aileron Therapeutics Inc Stock (ALRN) Company Profile

Name
Name
Aileron Therapeutics Inc
Name
Phone
(737) 802-1989
Name
Address
12407 N. MOPAC EXPY., AUSTIN, MA
Name
Employee
3
Name
Twitter
@Aileron_org
Name
Next Earnings Date
2024-11-18
Name
Latest SEC Filings
Name
ALRN's Discussions on Twitter

Compare ALRN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ALRN
Aileron Therapeutics Inc
0.00 45.72M 0 -12.94M -13.83M -2.84
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.58 26.10B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
442.05 111.96B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.35 42.96M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
81.20 6.39B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.28 63.52B 14.09B 4.50B 2.96B 39.28

Aileron Therapeutics Inc Stock (ALRN) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-28-25 Initiated Rodman & Renshaw Buy
Jul-24-17 Initiated BofA/Merrill Buy
Jul-24-17 Initiated Jefferies Buy
Jul-24-17 Initiated William Blair Outperform

Aileron Therapeutics Inc Stock (ALRN) Latest News

pulisher
May 27, 2025

Rein Therapeutics Announces First Patient Dosed In Renew Phase 2 Trial Of Lti-03 In Patients With Ipf - marketscreener.com

May 27, 2025
pulisher
May 22, 2025

Advancing Oxygen-Based Therapies: Hypoxia Treatment Market - openPR.com

May 22, 2025
pulisher
May 17, 2025

Rein Therapeutics Reports Q1 2025 Financial Results - TipRanks

May 17, 2025
pulisher
May 15, 2025

Rein Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Update - marketscreener.com

May 15, 2025
pulisher
May 12, 2025

Rein Therapeutics Announces Initiation Of Renew Phase 2 Trial Of Lti-03 In Patients With Ipf - marketscreener.com

May 12, 2025
pulisher
May 12, 2025

Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF - marketscreener.com

May 12, 2025
pulisher
May 01, 2025

Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF - marketscreener.com

May 01, 2025
pulisher
Apr 30, 2025

Rein Therapeutics to Present at The Citizens Life Sciences Conference 2025 - marketscreener.com

Apr 30, 2025
pulisher
Apr 23, 2025

Rein Therapeutics Granted Two Patents Covering The Novel Formulation And Administration Methods Of Dry Powder LTI-03 For Treatment Of Respiratory Diseases - marketscreener.com

Apr 23, 2025
pulisher
Apr 17, 2025

Hypoxia Treatment Market Growth: From $77.6M in 2022 to $134.3M - openPR.com

Apr 17, 2025
pulisher
Apr 15, 2025

Rein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F - PR Newswire

Apr 15, 2025
pulisher
Apr 07, 2025

Rein Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - Longview News-Journal

Apr 07, 2025
pulisher
Apr 04, 2025

RNTX stock touches 52-week low at $1.6 amid market challenges - Investing.com

Apr 04, 2025
pulisher
Apr 03, 2025

Aileron Therapeutics, Inc. Announces New Appointments - MarketScreener

Apr 03, 2025
pulisher
Mar 28, 2025

Peripheral T-cell Lymphoma Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Revenue, Statistics, Companies & Growth Analysis Report by DelveInsight - The Globe and Mail

Mar 28, 2025
pulisher
Mar 28, 2025

Reflecting On Productivity Software Stocks’ Q4 Earnings: Dropbox (NASDAQ:DBX) - The Globe and Mail

Mar 28, 2025
pulisher
Mar 28, 2025

Artivion (AORT): Buy, Sell, or Hold Post Q4 Earnings? - The Globe and Mail

Mar 28, 2025
pulisher
Mar 28, 2025

Better Artificial Intelligence Stock: SoundHound AI vs. C3.ai - The Globe and Mail

Mar 28, 2025
pulisher
Mar 27, 2025

Did Robinhood Just Say Checkmate to SoFi? - The Globe and Mail

Mar 27, 2025
pulisher
Mar 26, 2025

Firing on All Cylinders: Benchmark (NYSE:BHE) Q4 Earnings Lead the Way - The Globe and Mail

Mar 26, 2025
pulisher
Mar 25, 2025

Stocks in play: i-80 GOLD CORP. - The Globe and Mail

Mar 25, 2025
pulisher
Mar 20, 2025

Lucid (LCID): Buy, Sell, or Hold Post Q4 Earnings? - The Globe and Mail

Mar 20, 2025
pulisher
Mar 17, 2025

Are XPeng (XPEV) Traders Overpricing Options Ahead of Q4 Earnings? - The Globe and Mail

Mar 17, 2025
pulisher
Mar 14, 2025

Will Gasoline Prices Head Higher During the 2025 Driving Season? - The Globe and Mail

Mar 14, 2025
pulisher
Feb 25, 2025

Snowflake (SNOW) Q4 Earnings Report Preview: What To Look For - The Globe and Mail

Feb 25, 2025
pulisher
Feb 17, 2025

Chemotherapy Induced Anemia Drugs Market 2032: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Prevalence, NDA Approvals, Therapies, and Companies by DelveInsight - The Globe and Mail

Feb 17, 2025
pulisher
Feb 17, 2025

Chemotherapy Induced Anemia Drugs Market 2032: EMA, PDMA, FDA - openPR

Feb 17, 2025
pulisher
Feb 10, 2025

Hypoxia Treatment Market to Witness Substantial Growth by 2031 | - openPR

Feb 10, 2025
pulisher
Feb 05, 2025

Theratechnologies (NASDAQ:THTX) vs. Aileron Therapeutics (NASDAQ:ALRN) Head to Head Survey - Defense World

Feb 05, 2025
pulisher
Feb 04, 2025

Aileron Therapeutics Reports Q3 2024 Financial Results - MSN

Feb 04, 2025
pulisher
Jan 28, 2025

Pulmonary Fibrosis Clinical Trial Pipeline Appears Robust - GlobeNewswire

Jan 28, 2025
pulisher
Jan 27, 2025

Lockheed Martin Earnings: What To Look For From LMT - The Globe and Mail

Jan 27, 2025
pulisher
Jan 22, 2025

Aileron Therapeutics, Inc. announced that it has received $42 million in funding from a group of investors. - Marketscreener.com

Jan 22, 2025
pulisher
Jan 16, 2025

Aileron straps in for 2025 with a new name: Rein Therapeutics - Fierce Pharma

Jan 16, 2025
pulisher
Jan 14, 2025

Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for Retinoblastoma - Marketscreener.com

Jan 14, 2025
pulisher
Jan 13, 2025

Aileron Therapeutics, Inc. Announces Board Changes - Marketscreener.com

Jan 13, 2025
pulisher
Jan 13, 2025

Aileron Therapeutics, Inc. Announces Board Changes -April 01, 2019 at 06:16 am EDT - Marketscreener.com

Jan 13, 2025
pulisher
Jan 13, 2025

Aileron Therapeutics to be Included in the Russell Microcap® Index - Marketscreener.com

Jan 13, 2025
pulisher
Jan 13, 2025

Aileron Therapeutics Announces Appointments to Scientific Advisory Board -March 28, 2018 at 07:00 am EDT - Marketscreener.com

Jan 13, 2025
pulisher
Jan 13, 2025

Aileron Therapeutics Announces the Promotion of Richard J. Wanstall to Chief Financial Officer and Treasurer - Marketscreener.com

Jan 13, 2025
pulisher
Jan 13, 2025

Aileron Therapeutics Announces Board Appointments - Marketscreener.com

Jan 13, 2025
pulisher
Jan 13, 2025

Aileron Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference - Marketscreener.com

Jan 13, 2025
pulisher
Jan 13, 2025

Aileron Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights - Marketscreener.com

Jan 13, 2025
pulisher
Jan 13, 2025

Aileron Therapeutics, Inc. Announces Management Changes - Marketscreener.com

Jan 13, 2025
pulisher
Jan 13, 2025

Aileron Therapeutics Announces Management Changes - Marketscreener.com

Jan 13, 2025
pulisher
Jan 13, 2025

Aileron Therapeutics, Inc. Announces CEO Changes - Marketscreener.com

Jan 13, 2025
pulisher
Jan 13, 2025

Aileron Therapeutics Announces Management Changes -September 06, 2018 at 09:10 am EDT - Marketscreener.com

Jan 13, 2025
pulisher
Jan 13, 2025

Rein Therapeutics announces name change and new ticker By Investing.com - Investing.com Canada

Jan 13, 2025
pulisher
Jan 13, 2025

Rein Therapeutics announces name change and new ticker - Investing.com

Jan 13, 2025
pulisher
Jan 11, 2025

Aileron Therapeutics announces rebranding to Rein Therapeutics - MSN

Jan 11, 2025
pulisher
Jan 11, 2025

Geode Capital Management LLC Grows Position in Aileron Therapeutics, Inc. (NASDAQ:ALRN) - Defense World

Jan 11, 2025

Aileron Therapeutics Inc Stock (ALRN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Aileron Therapeutics Inc Stock (ALRN) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
UNIVERSITY OF TEXAS/TEXAS AM I
10% Owner
Jun 17 '24
Sale
3.25
4,707
15,298
1,746,549
UNIVERSITY OF TEXAS/TEXAS AM I
10% Owner
Jun 14 '24
Sale
3.30
1,900
6,270
1,751,256
UNIVERSITY OF TEXAS/TEXAS AM I
10% Owner
Jun 10 '24
Sale
3.30
9,577
31,604
1,768,250
UNIVERSITY OF TEXAS/TEXAS AM I
10% Owner
Jun 12 '24
Sale
3.25
9,342
30,362
1,753,156
UNIVERSITY OF TEXAS/TEXAS AM I
10% Owner
Jun 11 '24
Sale
3.26
5,752
18,744
1,762,498
UNIVERSITY OF TEXAS/TEXAS AM I
10% Owner
Jun 05 '24
Sale
3.30
6,291
20,760
1,783,851
UNIVERSITY OF TEXAS/TEXAS AM I
10% Owner
Jun 06 '24
Sale
3.29
4,284
14,104
1,779,567
UNIVERSITY OF TEXAS/TEXAS AM I
10% Owner
Jun 07 '24
Sale
3.26
1,740
5,664
1,777,827
$1.08
price up icon 1.89%
$30.14
price down icon 3.74%
$573.26
price down icon 1.32%
$304.56
price up icon 3.98%
$4.50
price down icon 3.02%
$490.28
price down icon 19.01%
Cap:     |  Volume (24h):